Role of Radiotherapy in Adrenocortical Carcinoma

被引:30
作者
Ho, Jennifer [1 ]
Turkbey, Baris [2 ]
Edgerly, Maureen [3 ]
Alimchandani, Meghna [4 ]
Quezado, Martha [4 ]
Camphausen, Kevin [1 ]
Fojo, Tito [3 ]
Kaushal, Aradhana [1 ]
机构
[1] NCI, Radiat Oncol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
关键词
Radiotherapy; radiation oncology; adrenocortical carcinoma; adrenal gland; palliative; adrenal cortex; ADRENAL-CORTICAL CARCINOMA; ADJUNCTIVE TREATMENT; RADIATION-THERAPY; MANAGEMENT; RECURRENCE; SURVIVAL; CANCER;
D O I
10.1097/PPO.0b013e31829e3221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Adrenocortical carcinoma (ACC) is a rare and highly malignant tumor usually diagnosed in an advanced stage. Radiation therapy has been a poorly studied and underutilized therapeutic option. Methods: This retrospective analysis reviewed treatment courses for 14 patients with pathologically confirmed ACC treated between 1997 and 2012. Two patients were treated adjuvantly following surgery, and 12 were treated with palliative intent. Patients presented with stage II (n = 4), stage III (n = 7), and stage IV (n = 3) disease. Patients had a mean age of 51.5 years. Ten patients received chemotherapy before radiotherapy (RT), and 12 patients received surgery before RT, before receiving radiation at a mean of 17.8 months after diagnosis. Results: In total, 20 sites were treated, 2 of which were in an adjuvant setting, and 18 of which were for palliative indications in 12 patients as follows: (1) pain/neuropathy (n = 10), (2) prophylactic treatment of asymptomatic recurrences (n = 3), and (3) prevention of imminent metastatic complications (n = 2), hemoptysis (n = 1), severe mass effect (n = 1), and brain metastasis (n = 1). Sites were treated to a median dose of 36.3 Gy (range, 17.5-60 Gy) in a median of 2.5 Gy/fraction (range, 1.8-4 Gy). At a mean follow-up of 22.0 months for the 2 patients given adjuvant RT, 1 patient did not have a local recurrence during a 14.3-month period of follow-up, and the other had a local recurrence 14.5 months after RT. At a mean follow-up of 11.3 months for the 12 patients receiving palliative RT, 10 patients had either a clinical or radiographic response. Of the courses of palliative RT that had adequate radiographic follow-up, 4 treatments (27%) resulted in a partial response. Eleven treatments (73%) that were able to be evaluated resulted in clinical improvement. Acute Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer toxicities observed in 7 patients included 3 grade 1, 4 grade 2, and 1 grade 3. No patient had acute toxicity of grade 4 or greater or any Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late toxicity of grade 1 or greater. Discussion: This report is one of the largest to date examining the role of modern radiation techniques in the management of ACC. We conclude that radiation can be effective in the management of metastatic ACC, palliating local symptoms, and preventing complications from large metastases. Radiation should be considered as an option in multimodality management of ACC patients.
引用
收藏
页码:288 / 294
页数:7
相关论文
共 37 条
[1]   Practical Considerations in the Evaluation and Management of Adrenocortical Cancer [J].
Balasubramaniam, Sanjeeve ;
Fojo, Tito .
SEMINARS IN ONCOLOGY, 2010, 37 (06) :619-626
[2]   Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma [J].
Bellantone, R ;
Ferrante, A ;
Boscherini, M ;
Lombardi, CP ;
Crucitti, P ;
Crucitti, F ;
Favia, G ;
Borrelli, D ;
Boffi, L ;
Capussotti, L ;
Carbone, G ;
Casaccia, M ;
Cavallaro, A ;
Del Gaudio, A ;
Dettori, G ;
Di Giovanni, V ;
Mazziotti, A ;
Marrano, D ;
Masenti, E ;
Miccoli, P ;
Mosca, F ;
Mussa, A ;
Petronio, R ;
Piat, G ;
Ruberti, U ;
Serio, G ;
Marzano, L .
SURGERY, 1997, 122 (06) :1212-1218
[3]   Adrenocortical Carcinoma in the United States Treatment Utilization and Prognostic Factors [J].
Bilimoria, Karl Y. ;
Shen, Wen T. ;
Elaraj, Dina ;
Bentrern, David J. ;
Winchester, David J. ;
Kebebew, Electron ;
Sturgeon, Cord .
CANCER, 2008, 113 (11) :3130-3136
[4]   Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell line [J].
Cerquetti, L. ;
Bucci, B. ;
Marchese, R. ;
Misiti, S. ;
De Paula, U. ;
Miceli, R. ;
Muleti, A. ;
Amendola, D. ;
Piergrossi, P. ;
Brunetti, E. ;
Toscano, V. ;
Stigliano, A. .
ENDOCRINE-RELATED CANCER, 2008, 15 (02) :623-634
[5]  
DIDOLKAR MS, 1981, CANCER-AM CANCER SOC, V47, P2153, DOI 10.1002/1097-0142(19810501)47:9<2153::AID-CNCR2820470908>3.0.CO
[6]  
2-6
[7]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[8]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[9]   Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma [J].
Fassnacht, Martin ;
Hahner, Stefanie ;
Polat, Buelent ;
Koschker, Ann-Cathrin ;
Kenn, Werner ;
Flentje, Michael ;
Allolio, Bruno .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) :4501-4504
[10]   Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma [J].
Gonzalez, Ricardo J. ;
Tamm, Eric P. ;
Ng, Chaan ;
Phan, Alexandria T. ;
Vassilopoulou-Sellin, Rena ;
Perrier, Nancy D. ;
Evans, Douglas B. ;
Lee, Jeffrey E. .
SURGERY, 2007, 142 (06) :867-874